Table 2.
The suppression of hapten-induced CD86 augmentation on MoDCs by anti-cytokine antibodies (%suppression)
| Antibodies | |||
|---|---|---|---|
| Chemicals | Control | Anti-TNF-α | Anti-IL-1β |
| Exp.1 | |||
| DNCB | 0 | 43 | 80 |
| NiCl2 | 0 | 13 | 7·3 |
| Exp. 2 | |||
| DNCB | 0 | 96 | 26 |
| NiCl2 | 0 | 23 | 28 |
| Exp. 3 | |||
| DNCB | ND | 57 | 57 |
| NiCl2 | ND | 0 | 0 |
| Exp. 4 | |||
| DNCB | ND | 2 | 60 |
| NiCl2 | ND | 0 | 0 |
| Exp. 5 | |||
| DNCB | 0 | 19 | 22 |
| NiCl2 | 0 | 19 | 0 |
Per cent suppression of mean fluorescence (MFI) was defined as [(MFI of hapten-stimulated DCs) − (MFI of hapten-stimulated DCs treated with cytokine antibody)] / [(MFI of hapten-stimulated DCs) − (MFI of non-treated controls)] × 100.